2022 World Conference on Lung Cancer (ePosters)-EP16.03-016. Targetable Alterations in Non-Small Cell Lung Cancer According to Age and Sex

EP16.03-016. Targetable Alterations in Non-Small Cell Lung Cancer According to Age and Sex

Pdf Summary

A study conducted by Mayo Clinic and Guardant Health aimed to understand the differences in targetable genomic alterations in non-small cell lung cancer (NSCLC) based on age and sex. The study included 34,278 patients with advanced NSCLC, and it was found that 90% of the patients had a genomic alteration detected in ctDNA.<br /><br />In terms of sex, females were found to have significantly higher numbers of alterations in EGFR, KRAS G12C, and ERBB2, while males were more likely to have MET amplifications and alterations in STK11 and TP53. However, there were no significant differences between males and females in the frequency of other alterations such as KRAS G12D/V and ALK.<br /><br />When it came to age, patients aged 70 and above were more likely to have alterations in genes such as EGFR exon 19 del/exon 20 ins/T790M, KRAS G12C/D, ALK, ROS1, BRAF, ERBB2, MET amplifications, STK11, and TP53. These patients were also more likely to have EGFR L861Q, MET exon 14 skipping, and PIK3CA alterations.<br /><br />The study also found that alterations in KRAS often coexisted with alterations in STK11 within the cohort of patients. The study used the Guardant Health database and assessed up to 83 genes using ctDNA.<br /><br />Overall, these findings suggest that there are differences in the distribution of targetable genomic alterations in NSCLC based on age and sex. Understanding these differences can help in individualizing treatment and improving outcomes for patients with NSCLC.

Asset Subtitle

ErinMarie O. Kimbrough

Meta Tag

Speaker ErinMarie O. Kimbrough

Topic Tumour Biology and Biomarkers - Molecular Profiling and Targeted Therapies

Keywords

Mayo Clinic

Guardant Health

NSCLC

genomic alterations

age

sex

ctDNA

EGFR

KRAS G12C

MET amplifications